Abstract:Aim: Accumulating evidence has explored the effect of mesalazine on irritable bowel syndrome (IBS). However, these studies remain inconsistent. Thus, a meta-analysis was conducted to estimate the role of mesalazine on IBS. Methods: PubMed, Medline, Embase, Web of Science, and the Cochrane Library Database were searched for all relevant randomized, controlled, blinded trials on mesalazine in patients with IBS between January 1980 and October 2018. All statistical analyses were performed using Revman 5.3 software. A fixed-effects model was adopted, 95% confidence intervals for SMD was calculated. Heterogeneity was evaluated by chi(2) test and I-2 statistic. Results: Five studies involving 387 participants were finally included in this meta-analysis. The results showed that the SMD for clinical efficacy on abdominal pain in IBS patients treated with mesalazine in comparison to placebo was 0.19 (95% CI=-0.01 to 0.39, P=.06), which was statistically non-significant but clinically important. For beneficial effect of abdominal bloating, the SMD was 0.05 (95% CI=-0.20 to 0.30, P=.70), which was statistically non-significant. In regard to clinical efficacy on defecation frequency per day, the results revealed that the SMD was 0.29 (95% CI=-0.14 to 0.73, P=.18), which was statistically non-significant but clinically important. As for beneficial effect of general well-being, we found that the SMD was 0.41 (95% CI=-0.75 to 1.58, P=.49), which was statistically non-significant. With respect to stool consistency, the SMD was 0.01 (95% CI=-0.31 to 0.33, P=.96), which was statistically non-significant. For the effect of defecation urgency severity in IBS patients treated with mesalazine in comparison to placebo, we detected a surprising result with an SMD of 0.54 (95% CI=0.05-1.04, P=.03), which was statistically significant. There was no significant difference between mesalazine group and placebo group on total mucosal immune cell counts of the patients with IBS with an SMD of -1.64 (95% CI=-6.17 to 2.89, P=.48) and there was also no significant difference in adverse reactions between two groups with an SMD of 1.05 (95% CI=0.76-1.46 P=.77). Conclusion: Mesalazine is not superior to placebo in relieving clinical symptoms of abdominal pain, abdominal bloating, and general well-being of IBS and has no advantage of reducing defecation frequency per day and immune cell infiltration and improving stool consistency though without adverse reactions of mesalazine compared with placebo. For defecation urgency severity, placebo is even superior to mesalazine for IBS patients. Thus, mesalazine might be a cost burden to patients without providing good effectiveness. In view of the small sample size of the current study and the differences in every experimental designs, this study has high heterogeneity and requires subsequent verification.

Effect of Mesalazine Combined with Trimebutine on Mast Cell and Related Inflammatory Mediators in Colonic Mucosa in Patients with Irritable Bowel Syndrome

Effectiveness of mesalazine to treat irritable bowel syndrome: A meta-analysis.

Clinical Efficacy of Glutamine in the Treatment of Irritable Bowel Syndrome

The Short-Term Efficacy of Bifidobacterium Quadruple Viable Tablet in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: Potentially Mediated by Metabolism Rather Than Diversity Regulation

Effect of mesalazine combined with probiotics on inflammation and immune function of patients with inflammatory bowel disease

Effects of Mesalazine Combined with Bifid Triple Viable on Intestinal Flora, Immunoglobulin and Levels of Cal, MMP-9, and MPO in Feces of Patients with Ulcerative Colitis.

Probiotics reduce inflammation and improve intestinal mucosal barrier in patients with inflammatory bowel disease

Pinaverium Bromide Combined with Bifid Triple Viable and Doxepin Therapy in Diarrhea-Dominant Irritable Bowel Syndrome

Therapeutic Effects of Mesalazine on Ulcerative Colitis and Changes of TNF-α and IL-8 in Sera

Clinical study of mesalazine alone and in combination with steroids in treatment of ulcerative colitis

Clinical Effects of Sulfasalazine Combined with Live Combined Bifidobacterium Lactobacillus and Enterococcus Capsules in Patients with Ulcerative Colitis

Effect of Combine Probiotics with Mesalazine on Ulcerative Colitis

Clinical Observation on the Combination of Bifid Tetragenous Viable Bacteria Tablets and Trimebutine Maleate Capsules to Treat the IBS

Experimental study on the treatment of ulcerative colitis with the combination of Tongxiening granule and Mesalazine

Effects of Mesalamine Combined with Live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules on Intestinal Mucosa Barrier Function and Intestinal Microbiota in Mildly Active Crohn's Disease Patients

Effect of Combination of Mesalazine and Bifico on Serum TNF-α,IL-10 Levels in Patients with Ulcerative Colitis

Effect of Probiotics Drug in Treatment of Mild and Moderate Ulcerative Colitis

A Probiotic Treatment Containing Lactobacillus, Bifidobacterium and Enterococcus Improves IBS Symptoms in an Open Label Trial

A Randomized, Controlled Study: Enteric-Coated Capsule of Bacillus Subtilis and Enterococcus Joint Trimebutine Maleate Tablets And/or Paroxetine Tablets in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Amelioration of inflammatory bowel disease by Bifidobacterium animalis subsp. lactis XLTG11 in combination with mesalazine

The efficacy and safety of mesalazine in the treatment o f inflammatory bowel disease--A nationwide multicenter clinical trial